Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Crenolanib + PRT062607|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Crenolanib||CP-868596|CP-868,596||FLT3 Inhibitor 61 PDGFR Inhibitor (Pan) 27||Crenolanib (CP-868596) is a type III receptor tyrosine kinase inhibitor of PDGFR-alpha/beta and FLT3, which results in inhibition of downstream signaling and prevents growth in tumor cells (PMID: 22745105, PMID: 24227820, PMID: 29137311, PMID: 31309543).|
|PRT062607||P505-15|BIIB057||SYK Inhibitor 15||PRT062607 is a selective inhibitor of SYK, which may lead to decreased tumor cell growth and increased sensitivity to chemotherapeutics (PMID: 23220742, PMID: 27406873).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CBL Q365_E366insSK FLT3 pos||hematologic cancer||sensitive||Crenolanib + PRT062607||Preclinical - Cell culture||Actionable||In a preclinical study, the addition of PRT062607 to treatment with Crenolanib resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762).||31943762|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|